Loading
companiesCompany
GEICAM Spanish Breast Cancer Group
aka GEICAM, Grupo Español de Investigación en Cáncer de Mama
Spain's national breast cancer research group, running adjuvant chemotherapy, endocrine and CDK4/6 inhibitor trials across more than 200 hospitals.
Overview
Founded in 1995, GEICAM brings together Spain's breast cancer investigators and has enrolled tens of thousands of patients in academic trials. GEICAM 9906 and 9805 shaped adjuvant taxane use, CIBOMA tested maintenance capecitabine in triple-negative disease, and PARSIFAL and FLIPPER studied palbociclib partners in hormone receptor-positive metastatic cancer. GEICAM co-runs global trials with the Breast International Group and the US cooperative groups and maintains the El Álamo registry and a tumour bank. Its chairman is a member of the OnCo people corpus.
Headquarters
Madrid, ES
Scorecard
All companies#105of 1243 companies, score 50
- approved products +6
- targets +2
- modalities +2
- regions +6
- 24-month regulatory events +4
- registry trials +30
1 approved, 0 in phase 3, 0 earlier, 1 targets, 240 registry studies. Formula on the scorecards page.
Website
Founded
1995
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-15.
Matched to GEICAM – Spanish Breast Cancer Group, including child institutions. 96 works · 630 citations · 54% open access · 25% clinical trials · 2% reviews.
Oncology works per year
162022
232023
242024
152025
182026
Most works
- Juan de la Haba-Rodríguez16 works
- Rosalía Caballero15 works
- Miguel Martín14 works
- Begoña Bermejo13 works
- José Á. García-Sáenz12 works
- Federico Rojo9 works
- Raúl Rincón9 works
- Javier Cortés9 works
- Lourdes Calvo8 works
- Susana Bezares8 works
Most cited
Ander Urruticoechea
Presidente (President) of GEICAM, the Spanish Breast Cancer Group
Medical oncologyBreast cancerAcademic clinical research
Medical oncologist from Gipuzkoa who became President of GEICAM, Spain's academic breast cancer research group, in 2025 on the retirement of its founder Miguel Martín.
Miguel Martín
Head of Medical Oncology, Hospital General Universitario Gregorio Marañón; Chairman, GEICAM
Breast cancerAdjuvant chemotherapyCooperative group trials
Miguel Martín is the founder of the Spanish breast cancer group GEICAM and a leader of adjuvant chemotherapy trials.
Sara López-Tarruella
Medical Oncologist, Hospital General Universitario Gregorio Marañón
Breast cancerTriple-negative diseaseNeoadjuvant trials
Sara López-Tarruella is a breast oncologist leading GEICAM neoadjuvant studies in triple-negative disease.
Notes
top- Adjuvant chemotherapy trials (GEICAM 9906, 9805)
- CDK4/6 inhibitor trials (PARSIFAL, FLIPPER)
- El Álamo registry and biobank
- BIG member group
Similar pages
not linked directly; found by shared links- CompanyAustrian Breast & Colorectal Cancer Study Group
Shares Breast International Group (BIG), Palbociclib, CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs) and the tag cooperative-group.
- CompanyBreast Cancer Trials
Shares Breast International Group (BIG), Endocrine therapy (SERMs, AIs, SERDs), HER2-positive breast cancer, Triple-negative breast cancer (TNBC) and the tag cooperative-group.
- CompanyETOP IBCSG Partners Foundation
Shares Breast International Group (BIG), Endocrine therapy (SERMs, AIs, SERDs), HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag cooperative-group.
- CompanyDanish Breast Cancer Group
Shares HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag cooperative-group.
- CompanyNSABP Foundation
Shares Endocrine therapy (SERMs, AIs, SERDs), HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag cooperative-group.
- CompanyOntario Clinical Oncology Group
Shares HR-positive / HER2-negative breast cancer and the tag cooperative-group.
- CompanyNRG Oncology
Shares Breast International Group (BIG), Triple-negative breast cancer (TNBC) and the tag cooperative-group.
- CompanyGerman Lymphoma Alliance
Shares Cytotoxic chemotherapy and the tag cooperative-group.
cancers
3fronts
1technologies
3drugs
1ApprovedSmall-molecule CDK4/6 inhibitor
Palbociclib · Ibrance